Principles of Clinical Pharmacology Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Principles of Clinical Pharmacology. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Principles of Clinical Pharmacology Indian Medical PG Question 1: Which of the following best demonstrates the variability in drug responsiveness among individuals?
- A. Potency
- B. Quantal Dose Response Curve (Correct Answer)
- C. Efficacy
- D. Graded Dose Response Curve
Principles of Clinical Pharmacology Explanation: ***Quantal Dose Response Curve***
- A **quantal dose-response curve** plots the percentage of individuals exhibiting a discrete, all-or-none effect against the log dose of a drug.
- This curve directly illustrates the **variability in drug responsiveness** within a population by showing the range of doses required to produce a specific effect in different individuals.
*Efficacy*
- **Efficacy** refers to the maximum effect a drug can produce, regardless of the dose.
- While efficacy is an important pharmacological parameter, it describes the drug's overall therapeutic potential, not the **individual variability** in response.
*Potency*
- **Potency** is a measure of the amount of drug needed to produce an effect of given intensity.
- It relates to the absolute dose required for a particular effect but does not directly demonstrate the **inter-individual differences** in biological response.
*Graded Dose Response Curve*
- A **graded dose-response curve** depicts the relationship between the dose of a drug and the **magnitude of the effect** in a **single biological unit** (e.g., an individual, a tissue, or a cell).
- This curve reflects the relationship between drug concentration and effect intensity, but not the **variability in response among different individuals** in a population.
Principles of Clinical Pharmacology Indian Medical PG Question 2: A 70 kg man was given a drug with a dose of 100 mg/kg body weight, twice daily. The half-life (t1/2) is 10 hours, the plasma concentration is 1.9 mg/mL, and the clearance is unknown. What is the clearance of this drug?
- A. 20 liter/hr
- B. K is 0.0693
- C. 0.22 L/hr (Correct Answer)
- D. 0.02 L/hr
Principles of Clinical Pharmacology Explanation: ***0.22 L/hr***
- To calculate clearance at steady state, we use the formula: **Clearance (Cl) = Dose Rate / Css** (steady-state plasma concentration).
- **Dose rate calculation**: 100 mg/kg × 70 kg × 2 doses/day = 14,000 mg/day = 583.33 mg/hr
- **Converting plasma concentration**: 1.9 mg/mL = 1900 mg/L
- **Clearance calculation**: Cl = 583.33 mg/hr ÷ 1900 mg/L = **0.307 L/hr**
- **Note**: The calculated value (0.307 L/hr) does not exactly match any option. The marked answer (0.22 L/hr) is the closest approximation among the given choices. This discrepancy may arise from rounding in the original question parameters or implicit assumptions about bioavailability/volume of distribution.
*0.02 L/hr*
- This value is approximately 15 times lower than the calculated clearance.
- Such low clearance would result in much higher plasma concentrations or require significantly lower dosing.
*20 liter/hr*
- This clearance is approximately 65 times higher than calculated, representing an unrealistically high value for this scenario.
- Such high clearance would result in very low plasma concentrations unless extremely high doses were administered.
*K is 0.0693*
- This represents the **elimination rate constant (k)**, calculated as k = 0.693/t1/2 = 0.693/10 hr = 0.0693 hr⁻¹.
- While mathematically correct for k, the question specifically asks for **clearance**, not the elimination rate constant.
- Clearance is related to k by: Cl = k × Vd (volume of distribution).
Principles of Clinical Pharmacology Indian Medical PG Question 3: Identify the correct match, regarding the drug and its adverse effect.
- A. Aliskiren - hypokalemia
- B. Hydralazine - heart failure
- C. Atenolol - hemolytic anemia
- D. Verapamil - constipation (Correct Answer)
Principles of Clinical Pharmacology Explanation: ***Verapamil - Constipation***
- **Verapamil**, a **non-dihydropyridine calcium channel blocker**, frequently causes constipation due to its effect on smooth muscle in the gastrointestinal tract, leading to **decreased intestinal motility**.
- This adverse effect is common and often dose-dependent, making it a significant consideration in patient management.
*Aliskiren - hypokalemia*
- **Aliskiren**, a **direct renin inhibitor**, can cause **hyperkalemia** by reducing angiotensin II levels, which normally stimulate aldosterone secretion.
- It does not typically cause hypokalemia; rather, potassium-sparing effects are often observed.
*Hydralazine - heart failure*
- **Hydralazine** is a **vasodilator** used to treat hypertension and **heart failure** with reduced ejection fraction by reducing afterload.
- It does not cause heart failure; instead, it is often prescribed to improve cardiac function in patients with heart failure.
*Atenolol - hemolytic anemia*
- **Atenolol** is a **beta-blocker** primarily used for hypertension, angina, and arrhythmias.
- **Hemolytic anemia** is a rare adverse effect associated with certain drugs, but it is not a known or common side effect of atenolol.
Principles of Clinical Pharmacology Indian Medical PG Question 4: What is the mechanism of action of ticagrelor?
- A. P2Y12 receptor antagonist (Correct Answer)
- B. Cox inhibition
- C. Inhibition of thromboxane synthase
- D. GPIIb/IIIa inhibition
Principles of Clinical Pharmacology Explanation: ***P2Y12 receptor antagonist***
- **Ticagrelor** is an **oral antiplatelet drug** that reversibly binds to the **P2Y12 ADP receptor** on platelet surfaces.
- By blocking this receptor, it prevents **ADP-mediated platelet activation** and subsequent aggregation, reducing the risk of thrombotic events.
*Cox inhibition*
- **COX inhibitors** like **aspirin** prevent the synthesis of **thromboxane A2**, a powerful platelet aggregator.
- This mechanism is characteristic of **NSAIDs** and **aspirin**, not ticagrelor.
*GPIIB/IIIA inhibition*
- **GPIIb/IIIa inhibitors** (e.g., abciximab, eptifibatide, tirofiban) directly block the final common pathway for platelet aggregation by preventing **fibrinogen binding** to the GPIIb/IIIa receptor.
- While also an antiplatelet mechanism, this is distinct from ticagrelor's action on the P2Y12 receptor.
*Inhibition of thromboxane synthase*
- Inhibition of **thromboxane synthase** would reduce the production of **thromboxane A2**, similar to the effect of COX inhibition.
- This is not the primary mechanism of action for ticagrelor; drugs like **dazoxiben** or **picotamide** act through this pathway.
Principles of Clinical Pharmacology Indian Medical PG Question 5: In which phase of clinical trials is drug dosing typically determined?
- A. Phase 1 (Correct Answer)
- B. Phase 2
- C. Phase 3
- D. Phase 4
- E. Phase 0
Principles of Clinical Pharmacology Explanation: ***Phase 1***
- This phase involves a small group of **healthy volunteers** to assess the drug's safety, **pharmacokinetics (PK)**, and establish an initial dosing range.
- The primary goal is to determine a **safe dosage level**, establish the **maximum tolerated dose (MTD)**, and identify potential side effects.
- This is where drug dosing is **typically determined**.
*Phase 0*
- This is an exploratory phase involving **microdosing** studies with subtherapeutic doses.
- The goal is to gather preliminary PK/PD data, but **not to determine therapeutic dosing**.
*Phase 2*
- This phase involves a larger group of **patients** with the condition to be treated.
- The main goal is to evaluate the drug's **effectiveness** and further assess safety, but not primarily to determine initial dosing.
*Phase 3*
- This phase involves a large number of patients across multiple sites to confirm the drug's **efficacy** and monitor side effects in a broader population.
- Dosing strategies have generally been established in earlier phases, and this phase primarily validates them.
*Phase 4*
- This phase occurs **after a drug has been approved** and marketed.
- It involves ongoing surveillance to monitor long-term effects, collect additional information on safety, and identify new uses, but not initial dose determination.
Principles of Clinical Pharmacology Indian Medical PG Question 6: A drug is more likely to cause toxicity in elderly patients due to all of the following reasons except which of the following?
- A. decreased renal excretion of drugs
- B. decreased hepatic metabolism
- C. decreased volume of distribution (Correct Answer)
- D. increased receptor sensitivity
Principles of Clinical Pharmacology Explanation: ***decreased volume of distribution***
- A **decreased volume of distribution** would generally lead to a higher peak plasma concentration for a given dose, potentially increasing drug effect and thus toxicity, particularly for **hydrophilic drugs**.
- However, for drugs that primarily distribute into **fat** or have a large volume of distribution, age-related changes in body composition (e.g., increased body fat, decreased total body water) can actually lead to an **increased volume of distribution** for some lipophilic drugs.
*decreased renal excretion of drugs*
- **Aging** is associated with a decline in **glomerular filtration rate (GFR)** and **renal tubular function**, leading to reduced drug clearance.
- This results in a longer **half-life** and accumulation of renally excreted drugs, increasing the risk of **toxicity**.
*decreased hepatic metabolism*
- Liver size, blood flow, and the activity of some **cytochrome P450 enzymes** may decrease with age.
- This leads to reduced **first-pass metabolism** and slower systemic clearance of many hepatically metabolized drugs, increasing their **bioavailability** and plasma concentrations.
*increased receptor sensitivity*
- Elderly patients often exhibit altered **pharmacodynamic responses**, including **increased sensitivity** to certain drugs.
- This means a lower concentration of the drug at the receptor site can produce a greater therapeutic or toxic effect, making them more susceptible to **adverse drug reactions**.
Principles of Clinical Pharmacology Indian Medical PG Question 7: Which statement best describes first-order kinetics in pharmacokinetics?
- A. Absorption of the drug is independent of the serum concentration
- B. Elimination of the drug is proportional to the serum concentration (Correct Answer)
- C. Absorption of the drug is proportional to the serum concentration
- D. Elimination of the drug is independent of the serum concentration
Principles of Clinical Pharmacology Explanation: ***Elimination of the drug is proportional to the serum concentration***
- In **first-order kinetics**, a **constant fraction** (or percentage) of the drug is eliminated per unit of time.
- This means that as the **serum drug concentration** increases, the absolute amount of drug eliminated per unit time also increases proportionally.
*Absorption of the drug is independent of the serum concentration*
- Drug absorption is generally driven by factors like **concentration gradient**, surface area, and blood flow, and while it can be influenced by drug concentration, this statement does not define first-order kinetics of *elimination*.
- This statement is not the primary characteristic distinguishing first-order from zero-order kinetics regarding drug disposition.
*Elimination of the drug is independent of the serum concentration.*
- This describes **zero-order kinetics**, where a **constant amount** of drug is eliminated per unit of time, regardless of the serum concentration.
- In zero-order kinetics, the elimination rate becomes saturated, so the elimination process cannot keep up with higher drug concentrations.
*Absorption of the drug is proportional to the serum concentration*
- While drug absorption can be proportional to the concentration (especially through passive diffusion), first-order kinetics specifically refers to the **elimination phase** of pharmacokinetics.
- The rate of absorption can be a complex process and is not the defining characteristic for distinguishing first-order from zero-order *elimination*.
Principles of Clinical Pharmacology Indian Medical PG Question 8: Match the following drugs in Column A with their contraindications in Column B.
| Column A | Column B |
| :-- | :-- |
| 1. Morphine | 1. QT prolongation |
| 2. Amiodarone | 2. Thromboembolism |
| 3. Vigabatrin | 3. Pregnancy |
| 4. Estrogen preparations | 4. Head injury |
- A. A-1, B-3, C-2, D-4
- B. A-4, B-1, C-3, D-2 (Correct Answer)
- C. A-3, B-2, C-4, D-1
- D. A-2, B-4, C-1, D-3
Principles of Clinical Pharmacology Explanation: ***A-4, B-1, C-3, D-2***
- **Morphine** is contraindicated in **head injury** as it can increase intracranial pressure and mask neurological symptoms.
- **Amiodarone** is contraindicated in patients with **QT prolongation** due to its risk of inducing more severe arrhythmias like Torsades de Pointes.
- **Vigabatrin** is contraindicated during **pregnancy** due to its potential for teratogenicity and adverse effects on fetal development.
- **Estrogen preparations** are contraindicated in patients with a history of **thromboembolism** due to their increased risk of blood clot formation.
*A-1, B-3, C-2, D-4*
- This option incorrectly matches **Morphine** with QT prolongation and **Estrogen preparations** with head injury, which are not their primary contraindications.
- It also incorrectly links **Vigabatrin** with thromboembolism and **Amiodarone** with pregnancy.
*A-3, B-2, C-4, D-1*
- This choice incorrectly associates **Morphine** with pregnancy and **Vigabatrin** with head injury, which are not the most critical or direct contraindications.
- It also misaligns **Amiodarone** with thromboembolism and **Estrogen preparations** with QT prolongation.
*A-2, B-4, C-1, D-3*
- This option incorrectly matches **Morphine** with thromboembolism and **Amiodarone** with head injury, which are not their most significant contraindications.
- It also incorrectly links **Vigabatrin** with QT prolongation and **Estrogen preparations** with pregnancy.
Principles of Clinical Pharmacology Indian Medical PG Question 9: Which of the following best describes a Type B adverse drug reaction?
- A. Augmented effect of drug
- B. Effect seen on chronic use of drug
- C. Delayed effect of drug
- D. Unpredictable bizarre reaction (Correct Answer)
Principles of Clinical Pharmacology Explanation: ***Unpredictable bizarre reaction***
- Type B reactions are **unpredictable**, **bizarre**, and not directly related to the drug's known pharmacological actions.
- They often involve **immunological reactions** or genetic predispositions, such as allergies or idiosyncratic responses.
*Augmented effect of drug*
- This describes a **Type A** adverse drug reaction, which is predictable and results from an **exaggerated pharmacological effect** of the drug.
- It is typically dose-dependent and can be managed by adjusting the dosage.
*Effect seen on chronic use of drug*
- This description can apply to several types of adverse reactions, but it commonly relates to **Type C (chronic) reactions**, where effects occur only after prolonged exposure.
- These reactions might be due to **cumulative toxicity** or adaptive changes in the body.
*Delayed effect of drug*
- This aligns with **Type D (delayed) adverse drug reactions**, which manifest long after the drug exposure has ended or after a period of latency.
- Examples include **carcinogenesis** or teratogenesis, occurring months or years later.
Principles of Clinical Pharmacology Indian Medical PG Question 10: What is the treatment of choice for a 5-year-old child with bedwetting?
- A. No treatment
- B. Motivational therapy (Correct Answer)
- C. Imipramine
- D. Desmopressin
Principles of Clinical Pharmacology Explanation: ***Motivational therapy***
- This is the **first-line active treatment** for **primary nocturnal enuresis** in children, involving encouragement, positive reinforcement (star charts), rewards, and education about bladder control.
- It focuses on **behavioral strategies** and can be highly effective with parental involvement.
- When intervention is pursued at age 5, motivational therapy is preferred over pharmacological options due to safety and effectiveness.
*No treatment*
- At age 5, **watchful waiting with reassurance** is often appropriate since nocturnal enuresis is common at this age (affects 15-20% of 5-year-olds) and has a **spontaneous resolution rate of 15% per year**.
- However, when the question asks for "treatment of choice," it implies active intervention rather than observation alone.
- Active behavioral therapy is preferred when bedwetting causes distress or affects the child's self-esteem.
*Imipramine*
- **Imipramine** is a **tricyclic antidepressant** with anticholinergic effects that can reduce bladder contractions, but it has significant side effects including **cardiac arrhythmias** and is **not first-line treatment**.
- It is typically reserved for children ≥7 years after behavioral interventions fail, due to its potential adverse effects and high relapse rate after discontinuation.
*Desmopressin*
- **Desmopressin** is an **antidiuretic hormone analog** that reduces urine production overnight.
- While effective, it is typically reserved for children ≥6 years who are unresponsive to behavioral therapy or for **short-term situational use** (e.g., sleepovers, camps).
- Side effects include potential **hyponatremia** and high relapse rate after discontinuation.
More Principles of Clinical Pharmacology Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
and potency (ED50))